瑞银指，由于今年新生率回升，而中国飞鹤逾70%的销售都来自第二和第三期的初生婴儿配方奶粉，以及即将推出的生育资助，料公司2025年至2026年的收入会改善，同时上调今年至2026年的每股盈利预测分别3%至13%。China's Feihe (06186) rose nearly 3%. As of press release, it rose 2.6% to HK$5.92, with a turnover of HK$41.3438 million.
The Zhitong Finance App learned that China's Feihe (06186) rose nearly 3%. As of press release, it had risen 2.6% to HK$5.92, with a turnover of HK$41.3438 million.
According to a research report released by UBS, China's Feihe management said in Beijing last week that it expected sales in the second half of the year to be better than in the first half of the year, benefiting from rising sales trends in the third quarter and providing guidance on revenue and net interest rate growth this year due to a better product portfolio, which were 5% to 10% and more than 10%, respectively. The bank believes that the company's shares are undervalued compared to other consumer goods listed companies in Hong Kong, and raised the target price from 5.1 yuan to 6.65 yuan, with a “buy” rating.
According to UBS, due to the recovery in the birth rate this year, and more than 70% of China's Feihe sales come from the second and third stages of newborn formula and upcoming maternity grants, the company's revenue from 2025 to 2026 is expected to improve, while raising its earnings per share forecast for this year to 2026 by 3% to 13%, respectively.
